Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 200 results for early or locally advanced breast cancer

  1. Irreversible electroporation for treating primary lung cancer and metastases in the lung (HTG302)

    Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.

    HealthTech guidance
    Published
    23 February 2013
    View recommendations

    Sections for HTG302

  2. Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

    Discontinued Reference number: GID-TA10803

    Technology appraisal guidance
    Discontinued

  3. Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]

    In development Reference number: GID-TA11862 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

    Technology appraisal guidance
    Discontinued

  5. Sunitinib in combination with capecitabine for the treatment of advanced and/or metastatic breast cancer [ID319]

    Discontinued Reference number: GID-TAG410

    Technology appraisal guidance
    Discontinued

  6. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued Reference number: GID-TAG387

    Technology appraisal guidance
    Discontinued

  7. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)

    Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    5 February 2025

    Sections for TA1037

  8. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued Reference number: GID-TAG404

    Technology appraisal guidance
    Discontinued

  9. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]

    Awaiting development Reference number: GID-TA11489 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]

    In development Reference number: GID-TA10960 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued Reference number: GID-TA10570

    Technology appraisal guidance
    Discontinued

  12. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development Reference number: GID-TA11022 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    In development Reference number: GID-TA11535 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema (HTG717)

    Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.

    HealthTech guidance
    Published
    16 April 2024
    View recommendations

    Sections for HTG717

  15. Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

    Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.

    Technology appraisal guidance
    Published
    22 February 2017
    View recommendations

    Sections for TA432